Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies

Inclusion Criteria: * Age ≥ 2 years of age and \< 21 years of age at time of study enrollment * Able to swallow genistein or take it with a puree. * Patients must have a diagnosis of recurrent or refractory solid tumors, including Central Nervous System tumors, lymphoma or leukemia for which standard curative measures do not exist or are no longer effective * For solid tumors, patients must have either measurable or evaluable disease. For leukemia, patients must have \> 5% blasts in the bone marrow. * Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy. * Performance level: Karnofsky ≥50% for patients ≥ 16 years of age or Lansky ≥ 50% for patients \< 16 years of age * Life expectancy at least one month * Patients must have adequate bone-marrow function * Patients must have normal organ as defined below: (total bilirubin ≤ 24microM/L), Amylase/pancreatic amylase≤1.5 × institutional upper limit of normal, Aspartate Aminotransferase (AST) /Alanine Aminotransferase (ALT) ≤2.5 × institutional upper limit of normal, creatinine clearance ≥60 mL/min/1.73 m2. OR creatinine according to age/gender * Nervous system disorders (CTCAE v4) resulting from prior therapy must be ≤ Grade 2 * Participants of child-bearing potential and men must agree to use adequate contraception for the duration of study treatment, and 4 months after completion of decitabine and genistein administration. * All patients and/or their parents or legally authorized representatives must sign a written informed consent Exclusion Criteria: * Prior decitabine or genistein therapy. * Patients who are receiving any other investigational agents. * Nasogastric or gastrostomy (or equivalent) administration of genistein is not allowed. * Patients with known exclusive non-measurable leptomeningeal disease at enrolment should be excluded from this clinical trial. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine and genistein. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (receiving antibiotics), symptomatic heart or lung disease, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant or breast-feeding women are excluded from this study. All girls of child bearing potential must have a negative pregnant test prior to enrolment. * Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.